NIKKEI 225
39,599.74 +16.66 (+0.04%) HANG SENG
17,718.61 +2.11 (+0.01%) CRUDE OIL
82.00 +0.46 (+0.56%) GOLD FUTURES
2,330.80 -8.80 (-0.38%) DOW
39,118.86 -45.24 (-0.12%) Bitcoin GBP
50,016.81 +2,111.55 (+4.41%)
URGN Jul 2024 12.500 put
| Previous close | 0.1300 |
| Open | 0.1300 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 12.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1300 - 0.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Investor's Business DailyUroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday. IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Business WireUroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 18, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ordinary share, and, to certain investors in lieu of issuing ordinary shares, pre-funded warrants to purchase 1,142,857 ordinary shares at a purchase price of $17.499 per pre
GlobeNewswireUroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purch
